Reduced MAP2 immunoreactivity (MAP2-IR) has been reported in diverse brain regions in schizophrenia and has been described as a “molecular hallmark” of the disorder (Marchisella et al., 2016). The gene discussed is MAP2; the disease is schizophrenia.